1. Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE).
- Author
-
Rusthoven, Chad, Staley, Alyse, Gao, Dexiang, Yomo, Shoji, Bernhardt, Denise, Wandrey, Narine, El Shafie, Rami, Kraemer, Anna, Padilla, Oscar, Chiang, Veronica, Faramand, Andrew, Palmer, Joshua, Zacharia, Brad, Wegner, Rodney, Hattangadi-Gluth, Jona, Levy, Antonin, Bernstein, Kenneth, Mathieu, David, Cagney, Daniel, Chan, Michael, Grills, Inga, Lee, Cheng-Chia, Sheehan, Jason, Kluwe, Christien, Patel, Samir, Halasz, Lia, Andratschke, Nicolaus, Deibert, Christopher, Verma, Vivek, Trifiletti, Daniel, Cifarelli, Christopher, Debus, Jürgen, Combs, Stephanie, Sato, Yasunori, Higuchi, Yoshinori, Aoyagi, Kyoko, Brown, Paul, Alami, Vida, Niranjan, Ajay, Lunsford, L, Kondziolka, Douglas, Camidge, D, Kavanagh, Brian, Robin, Tyler, Serizawa, Toru, Yamamoto, Masaaki, and Braunstein, Steve
- Subjects
Humans ,Carcinoma ,Non-Small-Cell Lung ,Lung Neoplasms ,Retrospective Studies ,Radiosurgery ,Prospective Studies ,Small Cell Lung Carcinoma ,ErbB Receptors ,Brain Neoplasms - Abstract
INTRODUCTION: Historical reservations regarding stereotactic radiosurgery (SRS) for small-cell lung cancer (SCLC) brain metastases include concerns for short-interval and diffuse central nervous system (CNS) progression, poor prognoses, and increased neurological mortality specific to SCLC histology. We compared SRS outcomes for SCLC and non-small cell lung cancer (NSCLC) where SRS is well established. METHODS: Multicenter first-line SRS outcomes for SCLC and NSCLC from 2000 to 2022 were retrospectively collected (n = 892 SCLC, n = 4785 NSCLC). Data from the prospective Japanese Leksell Gamma Knife Society (JLGK0901) clinical trial of first-line SRS were analyzed as a comparison cohort (n = 98 SCLC, n = 814 NSCLC). Overall survival (OS) and CNS progression were analyzed using Cox proportional hazard and Fine-Gray models, respectively, with multivariable adjustment for cofactors including age, sex, performance status, year, extracranial disease status, and brain metastasis number and volume. Mutation-stratified analyses were performed in propensity score-matched retrospective cohorts of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) positive NSCLC, mutation-negative NSCLC, and SCLC. RESULTS: OS was superior for patients with NSCLC compared to SCLC in the retrospective dataset (median OS = 10.5 vs 8.6 months; P
- Published
- 2023